high-risk/end-stage patient with functional mr: should we treat with anything? steven r. debeer, md...
TRANSCRIPT
Controlled Intermittent Asystole: Pharmacologic Potentiation of Vagal-Induced Asystole
DisclosuresNone
Preoperative AssessmentPulmonary Function TesteingFVC:Post BD=1.23 (50%)FEV1:Post BD=0.78 (42%)DLCO:8.4 (45%)Current Medical ManagementBeta-blockerASAStatinARBAldosterone antagonistLoop diureticInhaled steroid/beta-agonistInsulin
TEE
EF=20%Severe global hypokinesisAkinetic apexMod-severe MRCentral secondary to restricted P2 scallop mobilityCoaptation length